EUVIMEDEUVIMED entdecken
Crossref

Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer

Catherine H Marshall iD, Lukasz P Gondek, Violet Daniels, Changxue Lu iD, Sergiu Pasca, Jiajun Xie, Mark C Markowski iD, Channing J Paller iD, Laura A Sena, Samuel R Denmeade iD, Jun Luo, Emmanuel S Antonarakis iD

The Prostate · 2024-07 · 84 (10) · 954-958

DOI: 10.1002/pros.24712 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, online erschienen am 20.04.2024. Verfasst von Catherine H Marshall und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Prostatic Neoplasms, Clonal Hematopoiesis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: V Foundation, Commonwealth Foundation, Prostate Cancer Foundation; Winn Career Development Award, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Poly ADP‐ribose polymerase (PARP) inhibitors are approved for the treatment of some men with advanced prostate cancer. Rare but serious side effects include myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The impact of PARP inhibitors on clonal hematopoiesis (CH), a potential precursor lesion associated with MDS and AML, is incompletely understood in prostate cancer. We hypothesized that PARP inhibitors would increase CH prevalence and abundance.

Methods

We prospectively enrolled participants with advanced prostate cancer treated with PARP inhibitors. The presence of CH was assessed from leukocytes using an ultra‐deep error‐corrected dual unique molecular identifiers sequencing method targeting 49 genes most commonly mutated in CH and myeloid malignancies. Variant allele frequencies (VAF) of ≥0.5% were considered clinically significant. Blood samples were collected before and after PARP inhibitor treatment.

Results

Ten men were enrolled; mean age of 67 years. Six patients had Gleason 7 disease, and four had Gleason ≥8 disease at diagnosis. Nine had localized disease at diagnosis, and eight had prior treatment with radiation. The mean time between pre‐ and post‐treatment blood samples was 11 months (range 2.6–31 months). Six patients (60%) had CH identified prior to PARP inhibitor treatment, three with multiple clones. Of 11 CH clones identified in follow‐up, 5 (45%) appeared or increased after treatment. DNMT3A, TET2, and PPM1D were the most common CH alterations observed. The largest post‐treatment increase involved the PPM1D gene.

Conclusion

CH alterations are frequently found after treatment with PARP inhibitors in patients with prostate cancer and this may be one mechanism by which PARP inhibitors lead to increased risk of MDS/AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsProstatic NeoplasmsClonal HematopoiesisHumansMaleAgedMiddle AgedProspective StudiesDisease ProgressionPrevalenceAged, 80 and overDNA-Binding ProteinsDioxygenases

Stichwörter der Autor:innen

PARP inhibitorsclonal hematopoiesisprostate cancer

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsTET2 protein, humanDNA-Binding ProteinsDioxygenases

Autor:innen und Institutionen

  • Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Medicine, University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, USA.

ORCID-Profile: Catherine H Marshall, Changxue Lu, Mark C Markowski, Channing J Paller, Samuel R Denmeade, Emmanuel S Antonarakis

Förderung

  • V Foundation
  • Commonwealth Foundation
  • Prostate Cancer Foundation; Winn Career Development Award, National Institutes of Health
  • National Capital Cancer Research Fund
  • V Foundation for Cancer Research
  • National Institutes of Health
  • Prostate Cancer Foundation

Zitieren

APA

Marshall, C. H., Gondek, L. P., Daniels, V., Lu, C., Pasca, S., Xie, J., Markowski, M. C., Paller, C. J., Sena, L. A., Denmeade, S. R., Luo, J., & Antonarakis, E. S. (2024). Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer. The Prostate, 84(10), 954-958. https://doi.org/10.1002/pros.24712

Vancouver

Marshall CH, Gondek LP, Daniels V, Lu C, Pasca S, Xie J, et al. Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer. The Prostate. 2024;84(10):954-958. doi:10.1002/pros.24712

BibTeX
@article{Marshall2024,
  author = {Marshall, Catherine H and Gondek, Lukasz P and Daniels, Violet and Lu, Changxue and Pasca, Sergiu and Xie, Jiajun and Markowski, Mark C and Paller, Channing J and Sena, Laura A and Denmeade, Samuel R and Luo, Jun and Antonarakis, Emmanuel S},
  title = {Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer},
  journal = {The Prostate},
  year = {2024},
  volume = {84},
  number = {10},
  pages = {954--958},
  doi = {10.1002/pros.24712}
}
Kostenlos starten →